CRVS Latest News, Press Relases and Analysis

All

Press Releases

16 hours ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

a month ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

a month ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

a month ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

2 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

2 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

4 months ago - By: The Motley Fool

Corvus (CRVS) Q2 Loss Beats Estimates

4 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

4 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

6 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

6 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

6 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

6 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

7 months ago - By: Yahoo Finance - Mentions: TAP COST CRK NRG

US beer slowdown “cyclical” and will ease, Molson Coors CEO says

7 months ago - By: Stocktwits - Mentions: VTI VXF

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased

7 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

7 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

8 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

8 months ago - By: Yahoo Finance - Mentions: META BP EPD NVDA ...

Meta Platforms, Inc. (META): Among Stocks That Could 10X Over the Next 2 Years

8 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

9 months ago - By: Stocktwits - Mentions: VXF IBB AVSC

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger

9 months ago - By: Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Corvus Pharmaceuticals, Inc.

CORVUS PHARMACEUTICALS INC (CRVS) Stock News

CRVS Latest News, Press Relases and Analysis

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 4, 2025

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Earnings Scheduled For August 7, 2025

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Corvus (CRVS) Q2 Loss Beats Estimates

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

US beer slowdown “cyclical” and will ease, Molson Coors CEO says

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Meta Platforms, Inc. (META): Among Stocks That Could 10X Over the Next 2 Years

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma